Ion Beam Applications SA
Valentin Archontidis has a diverse work experience that spans multiple industries and roles. Valentin began their career at Ecole Centrale Paris, where they were responsible for managing a team and collecting the apprenticeship tax. Valentin then joined Anheuser-Busch InBev for an internship and master thesis focused on wastewater recycling and low temperature energy recovery. After that, Valentin worked at McKinsey & Company, starting as a Business Analyst and progressing to roles including Junior Associate, Associate, Junior Engagement Manager, and eventually Engagement Manager. During their time at McKinsey, Valentin specialized in the Pharmaceutical industry, leading projects related to brand acceleration, growth initiatives, and financial modeling. Currently, they are employed at IBA as the Chief of Staff to the COO, where they drive various initiatives such as operational excellence and contract renegotiation with customers. Valentin's most recent role at IBA is as the Industrial Customer Success Director.
Valentin Archontidis earned a Bachelor's degree in Applied Economics from Université Paris Dauphine - PSL in 2013. Valentin also completed a double degree in Engineering Sciences from CentraleSupélec from 2011 to 2013. Additionally, they obtained a degree in Chemical Engineering from the University of Liège, where they studied from 2009 to 2015.
This person is not in any teams
Ion Beam Applications SA
4 followers
Ion Beam Applications SA (IBA) is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.